論文・技術情報追加のお知らせ

1. A Real-World Safety Profile in Neurological, Skin, and Sexual Disorders of Anti-Seizure Medications Using the Pharmacovigilance Database of the Korea Adverse Event Reporting System (KAERS).

抗てんかん薬の副作用はSCBsで皮膚障害が多く、非SCBsで神経系障害が多い

対象DB：FAERS,KAERS

2. Gastroparesis treatment options metoclopramide and prucalopride: analysis of the FDA adverse event reporting system (FAERS) database.

メトクロプラミドは遅発性ジスキネジアを、プルカロプリドは頭痛と下痢を引き起こす

対象DB：FAERS

3. A real-world pharmacovigilance study of polatuzumab vedotin based on the FDA adverse event reporting system (FAERS).

ポラツズマブベドチンの副作用として血液疾患や腎水腫が報告された

対象DB：FAERS

4. Disproportionality Analysis of Nusinersen in the Food and Drug Administration Adverse Event Reporting System: A Real-World Postmarketing Pharmacovigilance Assessment.

ヌシネルセンの副作用として肺炎、嘔吐、頭痛などが報告され、新たに敗血症や心停止も発見

対象DB：FAERS

5. Pulmonary haemorrhage and haemoptysis associated with bevacizumab-related treatment regimens: a retrospective, pharmacovigilance study using the FAERS database.

ベバシズマブ療法で肺出血・喀血リスク増加

対象DB：FAERS

6. A pharmacovigilance study of chronic kidney disease in diabetes mellitus patients with statin treatment by using the US Food and Drug Administration adverse event reporting system.

スタチン使用が糖尿病患者のCKDリスクを増加させる可能性

対象DB：FAERS

7. A real-world pharmacovigilance study of FDA adverse event reporting system events for atogepant.

アトゲパントの副作用調査で新たな信号を発見、追加研究が必要

対象DB：FAERS

8. Comparison of injective related reactions following ofatumumab and ocrelizumab in patients with multiple sclerosis: data from the European spontaneous reporting system.

2021年に承認されたオファツムマブとオクレリズマブの副作用報告を比較

対象DB：EudraVigilance

9. Retrospective analysis of neoplasms in patients using angiotensin receptor blockers.

ARBsと腫瘍発生の関連をEudraVigilance Data Analysis System （EVDAS）で調査

対象DB：EudraVigilance

10. Association between antidepressant use and delirium in older adults: an analysis of the World Health Organization's global pharmacovigilance database.

高齢者における抗うつ薬処方とせん妄の報告間の関連をVigiBaseデータで調査

対象DB：VigiBase

11. Global burden of anticancer drug-induced acute kidney injury and tubulointerstitial nephritis from 1967 to 2023.

抗がん治療に関連するAKIとTINの世界的な有病率とリスク評価

対象DB：VigiBase

12. A DPC Database Study on the Safety of Atezolizumab/Carboplatin/Etoposide in Extensive-Disease Small Cell Lung Cancer in Japanese Patients.

日本の進行小細胞肺癌治療におけるACE療法の安全性評価

対象DB：DPC

13. A DPC Database Study on the Safety of Atezolizumab/Bevacizumab/Carboplatin/Paclitaxel in Non-small Cell Lung Cancer in Japanese Patients.

日本の進行非扁平非小細胞肺癌治療におけるABCP療法の安全性評価

対象DB：DPC

14. Surgery on admission and following day reduces hip fracture complications: a Japanese DPC study.

日本の高齢者股関節骨折患者で、入院当日または翌日の手術が合併症と死亡率を低下させる

対象DB：DPC

15. Reduction in the need for surgery and mortality after early administration of fibrinolytics following empyema drainage.

早期のフィブリノリン薬投与は膿胸患者で手術と死亡率低下に有効

対象DB：DPC

16. Balloon aortic valvuloplasty bridge to transcatheter aortic valve replacement is associated with worse in-hospital mortality.

BAVブリッジを経たTAVRの入院死亡率は直接TAVRを行うより高い

対象DB：DPC

17. Association between Postoperative Adjuvant Vasodilator Therapy and In-Hospital Mortality for Non-Occlusive Mesenteric Ischemia: A Nationwide Observational Study.

術後血管拡張薬使用はNOMI患者の死亡率に影響なし

対象DB：DPC

18. Drug utilization pattern of romosozumab and other osteoporosis treatments in Japan, 2019-2021.

ロモソズマブの継続率向上が治療に重要

対象DB：JMDC,MDV

19. Improvement of medication adherence for desmopressin by adjusting the prescription dosage in male patients with overactive bladder: A claims database analysis.

デスモプレシンの投薬調整が高い服薬継続率に関連

対象DB：JMDC

20. Performance of CHA(2)DS(2)-VASc and HAS-BLED in predicting stroke and bleeding in atrial fibrillation and cancer.

がん患者のAFリスク評価にCHA(2)DS(2)-VAScは有効

対象DB：CPRD

21. Respiratory Syncytial Virus Hospital Admission Rates and Patients' Characteristics Before the Age of 2 Years in England, 2015-2019.

イングランドではRSV入院率が過小評価される

対象DB：CPRD

22. Glucosamine and cancer incidence in osteoarthritis: A prevalent new-user cohort design.

グルコサミン使用はがん発症率を低減しないと示唆する研究

対象DB：CPRD